New Drug Application of Ruxolitinib Phosphate Cream Approved in China General Announcement Filing viewer · member access Original SGX announcement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 General Announcement Filing viewer · member access Original SGX announcement
Innovative Oral JAK1 Inhibitor Povorcitinib Included In The List Of Breakthrough Therapeutic Drugs General Announcement Filing viewer · member access Original SGX announcement
New Drug Application of Class 1 Innovative Drug Y-3 for Injection for AIS Accepted in China General Announcement Filing viewer · member access Original SGX announcement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025 General Announcement Filing viewer · member access Original SGX announcement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025 General Announcement Filing viewer · member access Original SGX announcement
NDA for AD Indication of Anti-IL-4Ra Humanized Monoclonal Antibody Injection Accepted in China General Announcement Filing viewer · member access Original SGX announcement
Signing a Distribution Agreement for Ophthalmic Drugs Lucentis and Beovu General Announcement Filing viewer · member access Original SGX announcement
Approval of Drug Clinical Trials for Additional COPD Indication of Class 1 MG-K10 Injection General Announcement Filing viewer · member access Original SGX announcement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025 General Announcement Filing viewer · member access Original SGX announcement
Approval of Phase III Drug Clinical Trials for Chronic Spontaneous Urticaria Indication of MG-K10 General Announcement Filing viewer · member access Original SGX announcement
Positive Results from Phase 3 Clinical Trial of Ruxolitinib Cream in Chinese Patients with AD General Announcement Filing viewer · member access Original SGX announcement
Approval of Drug Clinical Trials for Uterine Fibroids Indication of Innovative Drug CMS-D002 General Announcement Filing viewer · member access Original SGX announcement
Signing Collaboration Agreements for Vecantoxatug Injection and Silevimig Injection General Announcement Filing viewer · member access Original SGX announcement
NOTIFICATION LETTER ON ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS General Announcement Filing viewer · member access Original SGX announcement
REMINDER LETTERS ON THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS General Announcement Filing viewer · member access Original SGX announcement
Annual Reports and Related Documents:: Annual Reports and Related Documents Filing viewer · member access Original SGX announcement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025 General Announcement Filing viewer · member access Original SGX announcement
Approval of Clinical Trials for Vitiligo and Hidradenitis Suppurativa Indications of Povorcitinib General Announcement Filing viewer · member access Original SGX announcement
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION General Announcement Filing viewer · member access Original SGX announcement
Half Yearly Results Financial Statements and Related Announcement Filing viewer · member access Original SGX announcement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 General Announcement Filing viewer · member access Original SGX announcement
New Drug Application for Improved New Drug ZUNVEYL Accepted in China General Announcement Filing viewer · member access Original SGX announcement
